

About the EURLSSG

The European Restless Legs Syndrome Study Group (EURLSSG) is a non-profit association of RLS experts who are actively involved in RLS research and dedicated to optimizing patient outcomes by continuously improving standards for diagnosis and treatment of RLS.


Intended Audience

Healthcare professionals who encounter RLS patients in their clinical practice, including general practitioners, neurologists, and psychiatrists.

Educational Objectives

During this meeting the faculty will:

- Assess the difficulties encountered in diagnosing RLS in clinical practice.
- Review the clinical evidence and available experience with dopaminergic agents and alpha-2-delta ligands and assess whether these agents should be used as first-line treatments.
- Review the clinical implications of the alternatives to first-line agents (e.g. iron therapy and opioids), and how and when should they be used, including in special patient populations and in the context of augmentation.
- Provide a better understanding of how to treat comorbid RLS.



European
Restless Legs
Syndrome Study
Group e.V.



Join us for the
**2nd European Course on
Diagnosis and Management
of Restless Legs Syndrome**

14th December 2019
in Munich, Germany



Faculty

Klaus Berger, Muenster, Germany
Yves Dauvilliers, Montpellier, France
Diego Garcia-Borreguero, Madrid, Spain
Birgit Högl, Innsbruck, Austria
Joke Jaarsma, Amsterdam, The Netherlands
Mauro Manconi, Lugano, Switzerland
Roselyne Rjisman, The Hague, The Netherlands
Barbara Schormair, Munich, Germany
Rosalia Silvestri, Messina, Italy



Foto: Bernd Roemmelt, München Tourismus

Supported by unrestricted educational grants from:


AoP Orphan
(3.500 €)



Habel Medizintechnik
(3.000,- €)



UCB Pharma GmbH
(1.500,- €)



Programme

8:30 a.m. - 3:30 p.m.

- Diagnosis of RLS, clinical course and comorbidities
- RLS pathophysiology and genetics
- Epidemiology of primary and symptomatic / comorbid forms
- RLS severity, diagnostic pathways, and mimics
- RLS therapeutic approaches:
Current guidelines and general introduction to pharmacological treatment options

Controversy:

Dopamine agonists should be the first line treatment for RLS

Alpha-2-delta ligands should be the first line treatment for RLS

- What is augmentation, and how should it be managed?
- Guidelines for iron therapy
- The patient's perspective
- Treatment guidelines in special conditions: pregnancy and children
- Managing RLS in renal failure, depression, and other comorbidities
- Interactive case discussions
- Q&A session and closing remarks

Participants will receive a certificate of attendance. CME accreditation pending from BLAEK, Bavarian Medical Association, Germany.



Manopteros - English Garden

Foto: Shahow Wall, München Tourismus

Christkindlmarkt Ginger Bread

Foto: Lukas Barth, München Tourismus

Further information

Registration:

Please download the registration form from our website.

Course attendees have the possibility of attending a joint dinner on Friday, 13th December with EURLSSG members.

The dinner is a great opportunity to socialize and share clinical concerns with international RLS experts.

Fees:

- Non-members: 250 €
- Members: 200 €
- Students: 180 €
- Dinner: 50 €

Contact:

EURLSSG-Office: office@eurlssg.org

For more details please visit: <http://www.eurlssg.org>